2026 Q2 Portfolio Activity
In 2026 Q2, Merck & Co., Inc. maintained a portfolio of 15 distinct positions. The most significant new addition was ENTRADA THERAPEUTICS INC, now representing 2.43% of the total fund value. They heavily accumulated shares in AKTIS ONCOLOGY INC, increasing the position by 799.1%. The fund also reduced its exposure to ENTRADA THERAPEUTICS INC by 93.9%.
Position History
hover any row below to update
Loading…
Merck & Co., Inc.
AUM $526M
Total Positions
15
Quarter
2026 Q2
Top Holding
PSNL (35.8%)
Top 10 Concentration
99.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-15 of 15
Merck & Co., Inc. Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PSNL
PERSONALIS INC
|
Healthcare | 35.75% | 25.60% |
#1
1
Prev: #2
|
7.0 |
—
|
no change | no change |
P
S
|
14,044,943 | $188,202,236 |
$5.78
+138.8%
|
2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | ||
|
MRNA
MODERNA INC
|
Healthcare | 30.71% | 33.56% |
#2
1
Prev: #1
|
6.5 |
—
|
no change | no change |
P
S
|
2,308,190 | $161,642,545 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 16.82% | 18.40% |
#3
Prev: #3
|
6.0 |
—
|
no change | no change |
P
S
|
772,165 | $88,544,161 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
N/A
AKTIS ONCOLOGY ...
|
|
Unknown | 5.83% | 4.88% |
#4
2
Prev: #6
|
3.8 |
—
|
no change | no change |
P
S
|
952,844 | $30,710,162 | — | 13F Filing | 2026-06-30 | 2026-08-07 | ||
|
N/A
EIKON THERAPEUT...
|
|
Unknown | 4.13% | 5.05% |
#5
Prev: #5
|
3.2 |
—
|
no change | no change |
P
S
|
1,666,666 | $21,749,991 | — | 13F Filing | 2026-06-30 | 2026-08-07 | ||
|
TRDA
ENTRADA THERAPE...
|
Healthcare | 2.43% | — |
#6
Prev: #—
|
4.5 |
—
|
1,739,768 | — |
NEW
|
1,739,768 | $12,804,692 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 1.72% | 1.94% |
#7
1
Prev: #8
|
1.7 |
—
|
no change | no change |
P
S
|
272,351 | $9,042,053 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
ALEC
ALECTOR INC
|
Healthcare | 1.35% | 2.18% |
#8
1
Prev: #7
|
1.5 |
—
|
no change | no change |
P
S
|
3,545,719 | $7,126,896 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
EVAX
EVAXION BIOTECH...
|
Healthcare | 0.71% | 1.29% |
#9
Prev: #9
|
1.3 |
—
|
no change | no change |
P
S
|
1,214,126 | $3,763,791 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.33% | 0.52% |
#10
Prev: #10
|
1.1 |
—
|
no change | no change |
P
S
|
93,414 | $1,716,015 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
N/A
XILIO THERAPEUT...
|
|
Unknown | 0.19% | 0.26% |
#11
Prev: #11
|
1.1 |
—
|
no change | no change |
P
S
|
105,982 | $1,015,308 | — | 13F Filing | 2026-06-30 | 2026-08-07 | ||
|
HURA
TUHURA BIOSCIEN...
|
Healthcare | 0.01% | 0.01% |
#12
2
Prev: #14
|
1.0 |
—
|
no change | no change |
P
S
|
19,445 | $45,501 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
NEUP
NEUPHORIA THERA...
|
Healthcare | 0.01% | 0.01% |
#13
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
10,027 | $43,818 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
CARM
CARISMA THERAPE...
|
Healthcare | 0.00% | 0.01% |
Sold All 😨
(Was: #12) |
0.0 |
—
|
-1,473,240 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-07 | |||
|
N/A
ENTRADA THERAPE...
|
|
Unknown | 0.00% | 6.28% |
Sold All 😨
(Was: #4) |
0.0 |
—
|
-1,739,768 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-06-30 | 2026-08-07 |
Showing 1-15 of 15 holdings